A phase II study of BMS 247550 (ixabepilone) in advanced renal cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2013
At a glance
- Drugs Ixabepilone (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Oct 2010 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
- 06 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.